247 related articles for article (PubMed ID: 28692640)
1. Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving.
Prusa AR; Kasper DC; Sawers L; Walter E; Hayde M; Stillwaggon E
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005648. PubMed ID: 28692640
[TBL] [Abstract][Full Text] [Related]
2. Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model.
Stillwaggon E; Carrier CS; Sautter M; McLeod R
PLoS Negl Trop Dis; 2011 Sep; 5(9):e1333. PubMed ID: 21980546
[TBL] [Abstract][Full Text] [Related]
3. Prevention of congenital toxoplasmosis in France using prenatal screening: A decision-analytic economic model.
Sawers L; Wallon M; Mandelbrot L; Villena I; Stillwaggon E; Kieffer F
PLoS One; 2022; 17(11):e0273781. PubMed ID: 36331943
[TBL] [Abstract][Full Text] [Related]
4. The Austrian Toxoplasmosis Register, 1992-2008.
Prusa AR; Kasper DC; Pollak A; Gleiss A; Waldhoer T; Hayde M
Clin Infect Dis; 2015 Jan; 60(2):e4-e10. PubMed ID: 25216688
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of serological prenatal screening to detect Toxoplasma gondii infections in Austria.
Prusa AR; Kasper DC; Olischar M; Husslein P; Pollak A; Hayde M
Neonatology; 2013; 103(1):27-34. PubMed ID: 23018152
[TBL] [Abstract][Full Text] [Related]
6. Cost-benefit analysis of screening for toxoplasmosis during pregnancy.
Lappalainen M; Sintonen H; Koskiniemi M; Hedman K; Hiilesmaa V; Ammälä P; Teramo K; Koskela P
Scand J Infect Dis; 1995; 27(3):265-72. PubMed ID: 8539552
[TBL] [Abstract][Full Text] [Related]
7. [Argentine Consensus of Congenital Toxoplasmosis].
Durlach R; Kaufer F; Carral L; Freuler C; Ceriotto M; Rodriguez M; Freilij H; Altcheh J; Vazquez L; Corazza R; Dalla Fontana M; Arienti H; Sturba E; Gonzalez Ayala S; Cecchini E; Salomon C; Nadal M; Gutierrez N; Guarnera E
Medicina (B Aires); 2008; 68(1):75-87. PubMed ID: 18416325
[TBL] [Abstract][Full Text] [Related]
8. Prevention of prenatal toxoplasmosis by serological screening of pregnant women in Austria.
Aspöck H; Pollak A
Scand J Infect Dis Suppl; 1992; 84():32-7. PubMed ID: 1290071
[TBL] [Abstract][Full Text] [Related]
9. [Cost-benefit analysis of screening for congenital toxoplasmosis].
Sagmeister M; Gessner U; Kind C; Horisberger B
Schweiz Med Wochenschr Suppl; 1995; 65():103S-112S. PubMed ID: 7716447
[TBL] [Abstract][Full Text] [Related]
10. Congenital Chagas Disease in the United States: Cost Savings through Maternal Screening.
Stillwaggon E; Perez-Zetune V; Bialek SR; Montgomery SP
Am J Trop Med Hyg; 2018 Jun; 98(6):1733-1742. PubMed ID: 29714163
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of prevention strategies for congenital toxoplasmosis: a critical review of medico-economic studies].
Binquet C; Wallon M; Quantin C; Gadreau M; Peyron F
Rev Epidemiol Sante Publique; 2002 Oct; 50(5):475-87. PubMed ID: 12471340
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of neonatal versus prenatal screening for congenital toxoplasmosis.
Binquet C; Lejeune C; Seror V; Peyron F; Bertaux AC; Scemama O; Quantin C; Béjean S; Stillwaggon E; Wallon M
PLoS One; 2019; 14(9):e0221709. PubMed ID: 31532766
[TBL] [Abstract][Full Text] [Related]
13. [Toxoplasmosis screening: tu felix Austria?].
Hassl A
Wien Klin Wochenschr; 1998 Jan; 110(2):66-7. PubMed ID: 9531683
[No Abstract] [Full Text] [Related]
14. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment protocol.
Gilbert R; Dunn D; Wallon M; Hayde M; Prusa A; Lebech M; Kortbeek T; Peyron F; Pollak A; Petersen E
Epidemiol Infect; 2001 Aug; 127(1):113-20. PubMed ID: 11561963
[TBL] [Abstract][Full Text] [Related]
15. [Prevention of congenital toxoplasmosis in France. Risk assessment. Results and perspectives of prenatal screening and newborn follow up].
Ambroise-Thomas P; Schweitzer M; Pinon JM; Thiebaugeorges O
Bull Acad Natl Med; 2001; 185(4):665-83; discussion 684-8. PubMed ID: 11503357
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting.
Mansergh G; Haddix AC; Steketee RW; Nieburg PI; Hu DJ; Simonds RJ; Rogers M
JAMA; 1996 Jul; 276(2):139-45. PubMed ID: 8656506
[TBL] [Abstract][Full Text] [Related]
17. Screening for toxoplasmosis during pregnancy: the situation in Belgium.
Naessens A
Arch Pediatr; 2003 Feb; 10 Suppl 1():18. PubMed ID: 12802958
[No Abstract] [Full Text] [Related]
18. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening.
Mauskopf JA; Paul JE; Wichman DS; White AD; Tilson HH
JAMA; 1996 Jul; 276(2):132-8. PubMed ID: 8656505
[TBL] [Abstract][Full Text] [Related]
19. Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening.
Perez-Zetune V; Bialek SR; Montgomery SP; Stillwaggon E
Am J Trop Med Hyg; 2020 May; 102(5):1086-1089. PubMed ID: 32100696
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of preventive programmes against congenital toxoplasmosis.
Stray-Pedersen B; Jenum P
Scand J Infect Dis Suppl; 1992; 84():86-96. PubMed ID: 1290083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
